Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2020 TO 2029]"
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=collection%3ACTG&lookfor=%22Rheumatoid+Arthritis%22&type=Subject
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=collection%3ACTG&lookfor=%22Rheumatoid+Arthritis%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=collection%3ACTG&lookfor=%22Rheumatoid+Arthritis%22&type=Subject
PubPharm (4.443)
1
A Phase 3b/4 Study in Rheumatoid Arthritis : A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis. - RA-BRIDGE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy : A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis. : A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy. - RA-BEAM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Efficacy and safety of GSK3196165 versus placebo and sarilumab in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors. : A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors. - contRAst-3
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Study of the Efficacy and Safety of Olokizumab in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy : A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy - Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND) : A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
Filgotinib Alone or in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have Not Yet Started Methotrexate Treatment : A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A study comparing the use of etanercept and methotrexate, used either alone or in combination, for maintaining remission in rheumatoid arthritis. : A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
A Phase 3b/4 Study in Rheumatoid Arthritis : A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis. - RA-BRIDGE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With L-001069957 21 mg Plus Low-Dose Aspirin, L- 01069957 42 mg Plus Low-Dose Aspirin, Celecoxib 400 mg Plus Low-Dose Aspirin, or Low-Dose Aspirin Alone - 12-Week NO-Rofecoxib Plus Aspirin Endoscopy Study : A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With L-001069957 21 mg Plus Low-Dose Aspirin, L- 01069957 42 mg Plus Low-Dose Aspirin, Celecoxib 400 mg Plus Low-Dose Aspirin, or Low-Dose Aspirin Alone - 12-Week NO-Rofecoxib Plus Aspirin Endoscopy Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[445]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Erscheinungsjahr: 2020-2029
Medienart
4.443
Aufsätze
4.443
E-Artikel
4.443
E-Ressourcen
Zeitschriftentitel
3.940
WHO International Clinical Trials Registry Plat...
503
ClinicalTrials.gov
Thema
4.443
610
3.386
Study Type: Interventional
1.601
Recruitment Status: Not yet recruiting
903
Study Type: Observational
894
Recruitment Status: Recruiting
865
Phase: Phase 3
822
Recruitment Status: Completed
609
Medical Condition: Rheumatoid Arthritis
552
Phase: Phase 2
470
Recruitment Status: Complete: follow-up complete
457
Arthritis
405
Arthritis, Rheumatoid
378
Medical Condition: Rheumatoid arthritis
331
Phase: Phase 4
284
Recruitment Status: Authorised-recruitment may ...
260
Medical Condition: rheumatoid arthritis
134
Medical Condition: Health Condition 1: M059- Rh...
132
Phase: Phase 1
120
Recruitment Status: Complete: follow-up continuing
118
Medical Condition: Moderately to Severely Activ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2020-
740
2023
1.755
2022
1.267
2021
681
2020
Alle anzeigen ...
weniger ...
Erscheinungsjahr(e)
Von:
Bis:
Sprache
4.223
Englisch
166
Unbestimmt
22
Niederländisch
20
Spanisch
4
Französisch
2
Afrikaans
2
Frisian
2
Italienisch
2
Schwedisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...